TherapeuticsMD (NASDAQ:TXMD) Releases Quarterly Earnings Results, Beats Expectations By $15.43 EPS

TherapeuticsMD (NASDAQ:TXMDGet Rating) posted its quarterly earnings data on Monday. The company reported $12.39 earnings per share for the quarter, beating the consensus estimate of ($3.04) by $15.43, MarketWatch Earnings reports. During the same period last year, the company earned ($5.50) earnings per share.

TherapeuticsMD Trading Down 4.6 %

Shares of TherapeuticsMD stock traded down $0.44 during trading hours on Wednesday, hitting $9.15. 3,144 shares of the company were exchanged, compared to its average volume of 800,001. The business has a 50-day moving average of $7.31 and a 200-day moving average of $8.30. The stock has a market capitalization of $80.98 million, a price-to-earnings ratio of -2.52 and a beta of 1.67. TherapeuticsMD has a 1 year low of $1.99 and a 1 year high of $43.36.

Analyst Ratings Changes

Several equities research analysts have recently commented on TXMD shares. StockNews.com cut TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Thursday, July 21st. Cantor Fitzgerald restated a “neutral” rating on shares of TherapeuticsMD in a research note on Wednesday, July 13th. Finally, HC Wainwright cut TherapeuticsMD from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 7th.

Insiders Place Their Bets

In other TherapeuticsMD news, major shareholder Rubric Capital Management Lp acquired 17,688 shares of the business’s stock in a transaction on Monday, July 18th. The stock was purchased at an average price of $6.03 per share, for a total transaction of $106,658.64. Following the completion of the transaction, the insider now owns 1,156,953 shares of the company’s stock, valued at approximately $6,976,426.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders acquired 662,580 shares of company stock worth $15,466,258. 8.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. State Street Corp raised its position in TherapeuticsMD by 0.3% in the first quarter. State Street Corp now owns 7,259,095 shares of the company’s stock worth $2,758,000 after acquiring an additional 19,452 shares in the last quarter. Renaissance Technologies LLC raised its position in TherapeuticsMD by 243.5% in the first quarter. Renaissance Technologies LLC now owns 3,147,599 shares of the company’s stock worth $1,196,000 after acquiring an additional 2,231,301 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of TherapeuticsMD by 727.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,860,361 shares of the company’s stock valued at $1,087,000 after buying an additional 2,514,618 shares in the last quarter. Millennium Management LLC increased its position in shares of TherapeuticsMD by 339.2% in the second quarter. Millennium Management LLC now owns 57,657 shares of the company’s stock valued at $574,000 after buying an additional 44,528 shares in the last quarter. Finally, Royal Bank of Canada increased its position in shares of TherapeuticsMD by 688.1% in the first quarter. Royal Bank of Canada now owns 788,446 shares of the company’s stock valued at $299,000 after buying an additional 688,399 shares in the last quarter. Hedge funds and other institutional investors own 33.91% of the company’s stock.

TherapeuticsMD Company Profile

(Get Rating)

TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.

Featured Stories

Earnings History for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.